![](/themes/TruffleTheme/static/img/building-bg/building-bg_ykki6o_c_scale,w_2076.jpg)
![abivaxlogo.jpeg](/assets/f1500x900-q85-p1/01e18948/abivaxlogo.jpeg)
Abivax secures € 15M non-dilutive financing from Kreos Capital
« We are very happy about the decision of Kreos Capital to provide us with this non-dilutive loan, as it allows Abivax to keep executing on its priority clinical programs in chronic inflammatory diseases according to plan » said Pr. Hartmut Ehrlich, CEO of Abivax.